Protected forms of pharmacologically active agents and uses...

Details Protected forms of pharmacologically active agents and uses... Protected forms of pharmacologically active agents and uses...

2008-08-20

2010-02-23

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C514S411000, C514S415000, C514S424000, C514S517000, C514S532000, C514S533000, C514S534000, C548S366700, C548S367100, C548S449000, C548S486000, C558S052000, C558S056000, C560S060000, C560S073000, C564S092000, C564S167000, C564S168000, C564S160000, C564S163000

Reissue Patent

active

RE041151

ABSTRACT:
In accordance with the present invention, there are provided normal modified forms of nonsteroidal anti-inflammatory drugs. Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provide the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects then typically observed with such agents.

REFERENCES:
patent: 4362738 (1982-12-01), Keck et al.
patent: 5077217 (1991-12-01), Matson et al.
patent: 5214191 (1993-05-01), Kirschenheuter et al.
patent: 5663416 (1997-09-01), Kirschenheuter et al.
patent: 5703073 (1997-12-01), Garvey et al.
patent: 5916910 (1999-06-01), Lai
patent: 5925673 (1999-07-01), Hellberg et al.
patent: 6177466 (2001-01-01), Sakaki et al.
patent: 6201151 (2001-03-01), Tsai et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6306842 (2001-10-01), Lai et al.
patent: 2006/0046967 (2006-03-01), Satyam
patent: 1140564 (1983-02-01), None
patent: 2926472 (1981-01-01), None
patent: 24282 (1981-03-01), None
patent: 0461043 (1991-12-01), None
patent: 0034871 (1993-08-01), None
patent: 0035305 (1996-09-01), None
patent: 1125410 (1968-08-01), None
patent: 64040458 (1989-02-01), None
patent: 64-040458 (1989-10-01), None
patent: 05-279330 (1993-10-01), None
patent: 98/16502 (1998-04-01), None
patent: 2001/062085 (2001-08-01), None
patent: 03/045896 (2003-06-01), None
patent: 2004/004648 (2004-01-01), None
Datta et al., Catalytically Distinct Antibodies Prepared by the Reactive Immunization versus Transition State Analogue Hapten Manifolds, 1999, J. Am. Chem. Soc. 121(45):10461-10467.
Lo et al., Reactive Immunization Strategy Generates Antibodies with High Catalytic Proficiencies, 1997, J. Am. Chem. Soc. 119(42):10251-10252.
Alonso et al., η-Deficient 2-(Arylsulfonyl) Ethyl Esters as Protecting Groups for Carboxylic Acids, 2003, Synthesis 2:277-287, Verlag.
Sarakinos et al., A Practical New Chiral Controller for Asymmetric Diels-Alder and Alkylation Reactions, 1999, Organic Letters 1(11):1741-1744.
Schnitzer et al., Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy of Orally Administered Etodolac and Nabumetone in Patients with Active Osteoarthritis of the Knee, 1995, Clinical Thera. 17(4):602-612.
Weaver et al., Comparison of the Efficacy and Safety of Oxaprozin and Nabumetone in the Treatment of Patients with Osteoarthritis of the Knee, 1995, Clinical Thera. 17(4):735-745.
Fleischmann et al., A Double-Masked Comparison of Naprelan and Nabumetone in Osteoarthritis of the Knee, 1997, Clinical Thera. 19(4):642-655.
Lipscomb et al., Gastric mucosal injury and adaption to oral and rectal administration of naproxen, 1996, Aliment Pharmacol. Ther. 10:133-138.
Hawthorne et al., Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis, 1991, Br. J. Clin. Pharmac. 32:77-83.
Kelly et al., Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product, 1996, The Lancet 348:1413-1416.
Evans et al., Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and performation: a record linkage case-control study, 1995, BMJ 311:22-26.
Weil et al., Prophylactic aspirin and risk of peptic ulcer bleeding, 1995, BMJ 310:827-830.
Banoob et al., Risk of gastric injury with enteric-versus nonenteric-coated aspirin, 2002, Ann. Pharmacother. 36:163-166.
Lanza et al., Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa, 1980, N. Eng. J. Med. 303:136-138.
Petroski, Endoscopic comparison of three aspirin preparations and placebo, 1993, Clin. Ther. 15:314-320.
Lanza et al., Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day, 1985, Dig. Dis. Sci. 30:509-512.
Hoftiezer et al., Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man, 1980, The Lancet 2:609-612.
Lengeling et al., Ulcerative ileitis encountered at ileo-colonoscopy: likely role of nonsteroidal agents, 2003, Clin. Gastroenterol. Hepatol. 1:160-169.
Puspok et al., Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon, 2000, Dis. Colon Rectum 43:685-691.
Kato et al., Cycloxygenase-1 and Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes, 2001, J. Pharm. Pharmacol. 53:1679-1685.
Bianchi Porro et al., Gastroduodenal tolerability of Nabumetone versus naproxen in the treatment of rheumatic patients, 1995, Am. J. Gastroenterol. 90:1485-1488.
Roth et al., A controlled study comparing the effects of Nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa, 1993, Arch. Intern. Med. 153:2565-2571.
Greb et al. Endoscopic studies of Nabumetone in patients with rheumatoid arthritis: a comparative endoscopic and histologic evaluation, 1987, Am. J. Med. 83(4B):19-24.
Roth, Sanford H., Endoscopy-controlled study of the safety of Nabumetone compared with naproxen in arthritis therapy, 1987, Am. J. med. 30(4B):25-30.
Weaver et al., Treatment of patients with osteoarthritis with rofecoxib compared with Nabumetone, 2006, J. Clin. Rheumatol. 12:17-25.
Kivitz et al., Efficacy and safety of refecoxib 12.5 mg versus Nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial, 2004, J. Am. Geriatric Soc. 52:666-674.
Van Gossum et al., Anorectal stenosis in patients with prolonged use of suppositories containing paracetamol and acetylsalicylic acid, 1993, Dig. Dis. Sci. 38:1970-1977.
D'Haens et al., Procitis and Rectal Stenosis Induced by Nonsteroidal Anti-inflammatory Suppositories, 1993, J. Clin. Gastroenterol. 17(3):207-212.
Ivey et al., Acute effect of systemic aspirin on gastric mucosa in man, 1980, Dig. Dis. Sci. 25:97-99.
Baskin et al., Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference, 1976, Ann. Intern. Med. 85:299-303.
Evans et al., Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure, 1995, QJM 88:551-557.
Goldstein et al., Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis, 2001, Am. J. Gastroenterol. 96:1019-1027.
Wolfe et al., Giant duodenal ulcers associated with the postoperative use of ketorolac: report of three cases, 1994, Am. J. Gastroenterol. 89:1110-1111.
Traversa et al., Gastroduodenal toxicity of different nonsteroidal anti-inflammatory drugs, 1995, Epidemiology 6:49-54.
Lanas et al., Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations, 2006, Gut 55:1731-1738.
Hansen et al., Comparison of intravenous and intragastric aspirin in production of antral gastric ulcers in cats, 1980, Proc. Soc. Exp. Biol. Med. 164:589-592.
Ligumsky et al., Rectal Administration of Nonsteroidal Antiinflammatory Drugs: effect on rat gastric ulcerogenicity and prostaglandin E2synthesis, 1990, Gastroenterology 98:1245-1249.
Ogiso et al., Pharmacokinetics of Indomethacin Ester Prodrugs: Gastrointestinal and Hepatic Toxicity and the Hydrolytic Capacity of Various Tissues in Rats, 1996, Biol. Pharm. Bull. 19(9):1178-1183.
Giraud et al., Interaction of Indomethacin and Naproxen with Gastric Surface-active Phospholipids: A Possible Mechanism for the Gastric Toxicity of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), 1999, Biochem. Pharmacol. 57:247-254.
Marzo et al., Absorption and Distribution of Naproxen in Rats Orally Treated with Naproxen Betainate Sodium Salt Monohydrate, 1997, Arzneim. Forsch/Drug Res. 47(1):381-384.
Bjarnason et al., Side Effects of Nonsteroidal Anti-inflammatory Drugs on the Small and Large Intestine in Humans, Special Reports and Reviews, 1993, Gastreoenterology 104:1832-1847.
Carson et al., The Relative Gastrointestinal Toxicity of

Affiliated with

Also associated with

Rating

Protected forms of pharmacologically active agents and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protected forms of pharmacologically active agents and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protected forms of pharmacologically active agents and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4207486